WO2003105990A2 - Materiau filtrant pour toxines, bacteries, virus et autres substances physiologiques nocives - Google Patents
Materiau filtrant pour toxines, bacteries, virus et autres substances physiologiques nocives Download PDFInfo
- Publication number
- WO2003105990A2 WO2003105990A2 PCT/EP2003/005957 EP0305957W WO03105990A2 WO 2003105990 A2 WO2003105990 A2 WO 2003105990A2 EP 0305957 W EP0305957 W EP 0305957W WO 03105990 A2 WO03105990 A2 WO 03105990A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- filter material
- material according
- aryl
- alkyl
- acids
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3204—Inorganic carriers, supports or substrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/20—Pathogenic agents
- A61M2202/203—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/20—Pathogenic agents
- A61M2202/206—Viruses
Definitions
- the invention relates to a filter material for toxins, bacteria, viruses and other physiological pollutants, which can be used in hemoperfusion to rid the blood of such pollutants.
- the filter material is based on compounds from the class of calixarenes and reosrcinarene.
- Hemoperfusion is one of the (most effective measures for extracorporeal elimination of toxins and pollutants.
- hemoperfusion In contrast to hemodialysis, hemoperfusion is able to eliminate lipophilic substances that are not suitable for dialysis from the blood. However, hemoperfusion is usually superior to substances capable of dialysis. An important side effect, which has not yet been eliminated, is the undesired adsorption of throinocytes, which can be in a range up to about 40%.
- a filter material which consists of a compound of the general formula I
- R H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with • 1 to 12 carbon atoms, amino acids, sugar or crown ether,
- Ri H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms, sulfonamides, amino acids, sugars, crown ethers, cyclodextrins, purine bases or pyridine bases,
- R H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms or amino acids
- Ri H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms, sulfona ide, amino acids, sugar, crown ethers, cyclodextrins, purine bases or pyrimidine bases,
- R 2 * alkyl or aryl
- R 3 and 4 0, where R 3 and R are bridged together via methylene, ethylene or quinoxaline
- the designated aromatic systems can be any heteroatoms, e.g. B. 0, S, N, have.
- the peculiarity of the solution according to the invention is based on the fact that the macromolecules used from the group of the calixarenes and resorcinarenes are easily accessible synthetically and can be modified universally. So you can open them up. Optimize various requirements regarding the substance classes of the toxins to be eliminated. It is particularly interesting in view of the fact that a large number of substances have hitherto been insufficiently eliminated, for example B. Paraquat and Diquat.
- any matrices known from the prior art can be used as the carrier.
- the filter material it is also possible for the filter material to contain or consist of biomatrixes such as cotton or cellulose.
- Micelle formers or compounds from the group cyclodextrins are preferably contained as additives.
- cyclodextrins are significantly more polar and hydrophilic than calixarenes or resorcinarenes, which means that. certain applications a higher hydrophilicity of the filter material than can be realized.
- the calixarenes or resorcinarenes of the general formulas I and II must be modified depending on the pollutant to be eliminated.
- the modification takes place from the point of view of optimizing the interaction between the filter material and the relevant target molecule, ie. H. the pollutant.
- hydrophilic groups in the compounds are necessary to ensure water solubility.
- modification options of the filter material are to be mentioned here only by way of example in order to implement special applications. This includes, on the one hand, modifying the filter material with sugars that can interact with bacteria, making them accessible for hemoperfusion, so that they can be filtered out of physiological fluids. By modifying the filter material with amino acids, an interaction with viruses can also be made possible, so that these can also be separated using hemoperfusion.
- the filter material provides that the compound of the general formulas I and II are modified with antibodies. This enables the rapid elimination of antigens due to antigen-antibody interactions. With aggressive viruses in particular, there is the possibility of removing antigens from the organism until the immune system has stabilized.
- the filter material is based on the fact that the compounds of the general formulas I and II have a high temperature resistance, which can be exploited in such a way that recyclable filter materials can be provided.
- Appropriate thermal treatment thermally decomposes the pollutants eliminated from the blood, while the compounds of the general formulas I and II contained in the filter material remain stable. Such thermal treatments are preferably carried out above 300 ° C. Compared to the filter materials known from the prior art, the inventive materials thus have a significantly higher thermal stability.
- the filter material is preferably integrated into common filter devices. This includes, for example, cartridges, frits, disks or membranes.
- the filter material according to the invention is preferably used for the hemoperfusion of physiological liquids.
- Blood, plasma or urine are only examples of physiological fluids.
- the subject according to the invention is intended to be explained in more detail with reference to the following figure and the examples, without restricting it to the exemplary embodiments mentioned.
- 1 shows a schematic structural model of the tetrasulfonic acid calix [4] arene-paraquat complex.
- a paraquat molecule shows the incorporation of a paraquat molecule into a tetrasulfonic acid calix [4] arene system.
- the paraquat is bound to the filter material via different interactions. This includes a cation-OH interaction 1, a cation- ⁇ interaction 2, a CH- ⁇ interaction 3 and a ⁇ - ⁇ interaction 4.
- the complex formation constant is very large and can be in the range 10 5 are up to 10 ⁇ . This means that paraquat is stored irreversibly and can thus be permanently removed from the bloodstream, for example by hemoperfusion.
- the sulfuric acid is added all at once to the calix [4] arene in a 100 ml three-necked flask with gas inlet and outlet devices.
- the apparatus is flushed with argon and the reaction mixture is stirred at 80 ° C. for about 4 hours.
- the course of the reaction is followed by taking a sample and checking the solubility in water. If the mixture is soluble in water without a residue, the reaction is stopped.
- the crude product is filtered off with a glass frit (4 A), dissolved in methanol (in order to remove remaining sulfuric acid) and precipitated with ethyl acetate.
- the white precipitate is dried in an oil pump vacuum-
- Paraquat is a very effective contact herbicide and as such has been widely used for many decades.
- the toxic effect on plants is based on the inhibition of photosynthesis by the formation of radical intermediates which prevent the NADP reduction. This hinders the transmission of energy. It is 'non-toxic to rapidly oxygen, reduced well waser- soluble compounds, whereby it is a good way to carry out the control of weeds in time selectively and relatively umweitschonend' in the field in the presence of light and.
- Paraquat has repeatedly resulted in numerous acute and chronic poisonings in humans when used in agriculture or when attempting suicide. Symptoms such as eye damage, kidney and liver damage, gastritis and lung diseases occur until death from suffocation. Therapeutic measures are limited because there is no specific antidote. Adsorption on activated carbon or carbon filters is weak, which is why stronger interactions with adsorbents are sought.
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003245917A AU2003245917A1 (en) | 2002-06-12 | 2003-06-06 | Filter material for toxins, bacteria, viruses, and other harmful physiological substances |
EP03737999A EP1526910A2 (fr) | 2002-06-12 | 2003-06-06 | Materiau filtrant pour toxines, bacteries, virus et autres substances physiologiques nocives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10226099.0 | 2002-06-12 | ||
DE10226099A DE10226099A1 (de) | 2002-06-12 | 2002-06-12 | Filtermaterial für Toxine, Bakterien, Viren und andere physiologische Schadstoffe |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003105990A2 true WO2003105990A2 (fr) | 2003-12-24 |
WO2003105990A3 WO2003105990A3 (fr) | 2004-04-01 |
Family
ID=29718988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/005957 WO2003105990A2 (fr) | 2002-06-12 | 2003-06-06 | Materiau filtrant pour toxines, bacteries, virus et autres substances physiologiques nocives |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1526910A2 (fr) |
AU (1) | AU2003245917A1 (fr) |
DE (1) | DE10226099A1 (fr) |
WO (1) | WO2003105990A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8556085B2 (en) | 2010-11-08 | 2013-10-15 | Stuart Bogle | Anti-viral device |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992012709A1 (fr) * | 1991-01-29 | 1992-08-06 | Genelabs Technologies, Inc. | Compositions macrocycliques d'aryle utilisees dans le traitement d'infections virales |
WO1994003164A1 (fr) * | 1992-08-06 | 1994-02-17 | Genelabs Technologies, Inc. | Inhibition et traitement de l'infection par un virus a enveloppe avec des composes de calix(n) arene |
US6136071A (en) * | 1996-02-28 | 2000-10-24 | Transdiffusia S.A. | Process for the recovery of volatile low molecular compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989008092A1 (fr) * | 1988-02-29 | 1989-09-08 | The Flinders University Of South Australia | Separation de composes organiques contenus dans des fluides |
AU1545395A (en) * | 1994-01-24 | 1995-08-08 | Stephen J. Harris | Calixarene-based compounds having antibacterial, antifungal, anticancer-hiv activity |
JPH11209740A (ja) * | 1998-01-19 | 1999-08-03 | Kurita Water Ind Ltd | ハロゲン化エチレン化合物の分離剤 |
-
2002
- 2002-06-12 DE DE10226099A patent/DE10226099A1/de not_active Withdrawn
-
2003
- 2003-06-06 AU AU2003245917A patent/AU2003245917A1/en not_active Abandoned
- 2003-06-06 WO PCT/EP2003/005957 patent/WO2003105990A2/fr not_active Application Discontinuation
- 2003-06-06 EP EP03737999A patent/EP1526910A2/fr not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992012709A1 (fr) * | 1991-01-29 | 1992-08-06 | Genelabs Technologies, Inc. | Compositions macrocycliques d'aryle utilisees dans le traitement d'infections virales |
WO1994003164A1 (fr) * | 1992-08-06 | 1994-02-17 | Genelabs Technologies, Inc. | Inhibition et traitement de l'infection par un virus a enveloppe avec des composes de calix(n) arene |
US6136071A (en) * | 1996-02-28 | 2000-10-24 | Transdiffusia S.A. | Process for the recovery of volatile low molecular compounds |
Non-Patent Citations (4)
Title |
---|
A. DONDONI ET AL CHEMISTRY - A EUROPEAN JOURNAL Bd. 3, Nr. 11, 1997, Seiten 1774 - 1782, XP001091340 * |
DATABASE CAPLUS AMERICAN CHEMICAL SOCIETY; 1999, XP002263941 gefunden im STN Database accession no. 1999:481646 -& CHEMICAL ABSTRACTS, Bd. 131, Nr. 10, 6. September 1999 (1999-09-06), Columbus, Ohio, US; abstract no.: 131813, XP002263940 & JP 11 209740 A (KURITA WATER INDUSTRIES LTD) 3. August 1999 (1999-08-03) * |
M.H.B GROTE GANSEY ET AL BIOCONJUGATE CHEM. Bd. 10, Nr. 4, 1999, Seiten 613 - 623, XP000831957 * |
R. AZHARI ET AL JOURNAL OF BIOMEDICAL MATERIALS RESEARCH Bd. 21, Nr. 1, 1987, Seiten 25 - 41, XP001091341 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8556085B2 (en) | 2010-11-08 | 2013-10-15 | Stuart Bogle | Anti-viral device |
Also Published As
Publication number | Publication date |
---|---|
EP1526910A2 (fr) | 2005-05-04 |
AU2003245917A8 (en) | 2003-12-31 |
WO2003105990A3 (fr) | 2004-04-01 |
DE10226099A1 (de) | 2004-01-08 |
AU2003245917A1 (en) | 2003-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3115608C2 (de) | Vorrichtung für die Adsorption von Blutproteinen | |
EP0533727B1 (fr) | MATERIAU ADSORBANT D'ELIMINATION SELECTIVE DE LDL ET/OU vLDL | |
DE2746942A1 (de) | Neue psoralenderivate | |
DE4331358A1 (de) | Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten | |
DE69834651T2 (de) | Filtermaterial zur entfernung von weissen blutkörperchen | |
EP1326708B1 (fr) | Adsorbant comportant des zones superficielles a modification differenciee, son procede de production et son utilisation | |
DE3932971C2 (de) | Zur Eliminierung von Biomakromolekülen, insbesondere LDL und Endotoxinen, aus Vollblut in extrakorporalem Kreislauf geeignetes Adsorbens | |
DE69530761T2 (de) | Methode und poröser träger zur entfernung von verunreinigungen | |
DE10197267T5 (de) | Eine Methode zur Extraktion von Tetrodotoxin | |
WO2006008085A1 (fr) | Dispositif et procede permettant d'isoler efficacement des acides nucleiques | |
DE69330458T3 (de) | Verfahren zur gewinnung eines hochreinen factor viii/von willebrand faktor komplexes durch anionenaustauschchromatographie | |
DE19900681B4 (de) | Verwendung von Anionaustauschermembranen zur Entfernung von Endotoxinen aus Nukleinsäure-haltigen Lösungen | |
WO2003105990A2 (fr) | Materiau filtrant pour toxines, bacteries, virus et autres substances physiologiques nocives | |
DE10011481A1 (de) | Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin, Verwendung des Adsorbens zur Herstellung eines Adsorbers und Adsorber mit dem Adsorbens | |
DE60131710T2 (de) | Verfahren zur Adsorption und Entfernung, und Verwendung eines Adsorbers für endogene Cannabinoide | |
EP1104674A1 (fr) | Colorants o-o'-dihydroxy azoiques dans des médicaments ayant une activité TPO-agoniste ou synergétique | |
DE3046565A1 (de) | Verfahren zur trennung von blutserumproteinen | |
WO2003024587A2 (fr) | Procede de purification de sang total | |
DE3715447C2 (de) | Verfahren zur Herstellung einer Mischung von O-(beta-Hydroxyethyl)-diosminen | |
DE10011482A1 (de) | Verfahren zum Herstellen eines Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin, Adsorbens und Verwendung des Adsorbens zur Herstellung eines Adsorbers | |
CN106928309B (zh) | 一种螺旋甾碱烷型糖苷生物碱及其制备方法与用途 | |
DE60317652T2 (de) | Verfahren zur Reinigung von Polyetherpolyolen | |
EP1602387B1 (fr) | Dispositif d'elimination des lipopolysaccharides et/ou de l'acide lipoteichoique des liquides contenant des proteines ainsi que son utlilisation pour fabriquer un moyen pour leurs elimination | |
DE2632115C2 (fr) | ||
WO1997033683A1 (fr) | Membranes specifiques de l'endotoxine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003737999 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003737999 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |